MIMETAS
Series B
MIMETAS develops organ-on-a-chip human tissue and disease models used in drug discovery and safety testing.
Founded
2013MIMETAS develops organ-on-a-chip human tissue and disease models used in drug discovery and safety testing.
MIMETAS offers the OrganoPlate organ-on-a-chip platform as its flagship product, supporting 3D cell culture under continuous perfusion for permeability, transport, migration, invasion, and co-culture assays without filter membranes. The platform underpins complementary lines including OrganoReady ready-to-use tissue models, OrganoAccess perfusable vascular models, and Assay Ready products such as the Caco-2 intestinal tubule model.
Beyond hardware, the company provides contract research services across immunology, oncology, metabolic, infectious, neurology, and ADME-toxicity research areas, building disease models for the liver, kidney, central nervous system, blood-brain barrier, and vasculature for pharmaceutical and food and nutrition customers.
MIMETAS operates in the organ-on-a-chip and 3D in vitro model market, which is growing as pharmaceutical companies adopt human-relevant models to replace animal testing, accelerated by the 2022 FDA Modernization Act 2.0 that allows alternative non-animal methods in drug applications. The company competes with Emulate, InSphero, TissUse, and CN Bio Innovations in a market led by Emulate and MIMETAS.
Demand is driven by pharmaceutical companies seeking to reduce late-stage drug trial failures and pipeline risk, with MIMETAS positioning its high-throughput OrganoPlate platform for ADME, safety, toxicology, and efficacy studies across drug discovery and food and nutrition research.
MIMETAS' OrganoPlate is positioned as the world's first mass-produced, quality-controlled organ-on-a-chip platform, offering high-throughput 3D cell culture under continuous perfusion without filter membranes. This combination of physiological relevance with the usability and throughput scientists expect from traditional methods differentiates it from lower-throughput organ-on-a-chip systems.
The company operates an integrated model combining proprietary hardware, ready-to-use Assay Ready tissue models, and contract research services, supported by cleanroom chip manufacturing in Enschede and offices across three continents. This vertical integration lets pharmaceutical customers access organ-on-a-chip data through products, services, or partnerships.